R&D for next-generation strategic products and the profit contribution of the pharmaceutical business
First written in FY2016-Q2. 13 of 36 entries say "Advanced", first in FY2016-Q3. Latest entry: FY2025.
No other company in this theme has enough history to compare yet.
- FY2025AchievedAnnual report
「The transfer of our Group's pharmaceutical business was completed on 1 December 2025.」
The previous focus on having the pharmaceutical business contribute to the Company's own profits was removed from the Group's continuing operations upon completion of its transfer to Shionogi & Co., Ltd. - FY2025-H1ReframedAnnual report
「We determined that the best course of action for further developing the drug discovery capabilities our Group has built over the years and delivering pharmaceuticals to more patients is to identify the value of both our pharmaceutical business and Torii Pharmaceutical and operate the business under Shionogi & Co., Ltd., a pharmaceutical company focused on creating innovative medicines.」
In addition to the previous approach centered on the pharmaceutical business's stable contribution to the Company's own profits, the strategic direction has shifted toward operating the business under Shionogi & Co., Ltd., with the aim of advancing drug discovery capabilities and delivering pharmaceuticals to patients. - FY2024Lower profit due to the absence of lump-sum income and higher R&D expensesAnnual report
「Revenue decreased 0.4% year on year despite growth in sales at Torii Pharmaceutical, due to the absence of lump-sum income related to a license agreement for JT out-licensed products recorded in the previous fiscal year and lower overseas royalty income. Adjusted operating profit decreased 47.0% year on year due to the impact of lower lump-sum income and increased R&D expenses.」
In the pharmaceutical business, profit declined despite growth in sales at Torii Pharmaceutical, due to the absence of lump-sum license income from the previous fiscal year, lower overseas royalty income and increased R&D expenses. - FY2024-H1Lower revenue and profit due to the absence of lump-sum incomeAnnual report
「Revenue decreased 7.5% year on year despite growth in sales in the dermatology and allergen fields at Torii Pharmaceutical, a consolidated subsidiary, due to the absence of lump-sum income related to a license agreement for out-licensed products in the previous fiscal year. Adjusted operating profit decreased 60.2% year on year due to the impact of the absence of lump-sum income from revenue and increased R&D expenses.」
In the pharmaceutical business, revenue decreased 7.5% and adjusted operating profit decreased 60.2% due to the absence of lump-sum income from out-licensed product licenses in the previous fiscal year and increased R&D expenses, despite growth in Torii Pharmaceutical's dermatology and allergen fields. - FY2024-Q1Lower revenue and profit due to the absence of lump-sum incomeAnnual report
「Revenue decreased 6.4% year on year despite growth in sales in the dermatology and allergen fields at Torii Pharmaceutical, a consolidated subsidiary, mainly due to the absence of lump-sum income from a license agreement for out-licensed products that was recorded in the same period of the previous year. Adjusted operating profit decreased 44.5% year on year due to lower revenue and increased R&D expenses.」
In the pharmaceutical business, revenue and profit declined due to the absence of lump-sum income from an out-licensed product license recorded in the same period of the previous year and increased R&D expenses, despite growth in certain fields at Torii Pharmaceutical. - FY2023AdvancedAnnual report
「Revenue increased 14.4% year on year due to lump-sum income related to a license agreement for out-licensed products and higher revenue at Torii Pharmaceutical, a consolidated subsidiary. Adjusted operating profit increased 56.2% year on year due to higher revenue despite increased R&D expenses.」
Revenue in the pharmaceutical business increased 14.4% and adjusted operating profit increased 56.2% due to lump-sum income related to a license agreement for out-licensed products and higher revenue at Torii Pharmaceutical. - FY2023-Q3AdvancedAnnual report
「Revenue increased 17.0% year on year due to lump-sum income related to a license agreement for out-licensed products and higher revenue at Torii Pharmaceutical, a consolidated subsidiary. Adjusted operating profit increased 80.5% year on year due to higher revenue despite increased R&D expenses.」
In the pharmaceutical business, revenue increased 17.0% and adjusted operating profit increased 80.5% due to lump-sum income related to a license agreement for out-licensed products and higher revenue at Torii Pharmaceutical. - FY2023-Q2AdvancedAnnual report
「Revenue increased 21.3% year on year due to lump-sum income related to a license agreement for out-licensed products and higher revenue at Torii Pharmaceutical, a consolidated subsidiary. Adjusted operating profit increased 106.5% year on year due to higher revenue despite increased R&D expenses.」
In the pharmaceutical business, revenue increased 21.3% and adjusted operating profit increased 106.5% due to lump-sum income related to a license agreement for out-licensed products and higher revenue at Torii Pharmaceutical. - FY2023-Q1AdvancedAnnual report
「Revenue increased 17.1% year on year due to lump-sum income related to a license agreement for out-licensed products and higher revenue at Torii Pharmaceutical, a consolidated subsidiary. Adjusted operating profit increased 51.6% year on year due to higher revenue despite increased R&D expenses.」
In the pharmaceutical business, revenue increased 17.1% and adjusted operating profit increased 51.6% due to lump-sum income related to a license agreement for out-licensed products and higher revenue at Torii Pharmaceutical. - FY2022Higher revenue, broadly flat profitAnnual report
「Revenue increased 3.1% year on year as higher revenue at Torii Pharmaceutical, a consolidated subsidiary, more than offset the absence of the prior fiscal year's lump-sum income related to out-licensed products and lower overseas royalty income. Adjusted operating profit was at the same level as the previous fiscal year, despite higher revenue, due to increased R&D expenses and other costs at Torii Pharmaceutical.」
In the pharmaceutical business, revenue increased 3.1% year on year due to higher revenue at Torii Pharmaceutical, while adjusted operating profit remained at the same level as the previous fiscal year. - FY2022-Q3Continued higher sales and profitsAnnual report
「Revenue increased 5.1% year on year due to higher revenue at Torii Pharmaceutical, a consolidated subsidiary. Adjusted operating profit increased 10.0% year on year due to higher revenue despite increased R&D expenses.」
In the pharmaceutical business, revenue increased 5.1% and adjusted operating profit increased 10.0%, driven by higher revenue at Torii Pharmaceutical. - FY2022-Q2Higher revenue and profitsAnnual report
「Revenue increased 6.1% year on year due to higher revenue at Torii Pharmaceutical, a consolidated subsidiary. Adjusted operating profit increased 36.8% year on year due to higher revenue.」
In the pharmaceutical business, revenue increased 6.1% year on year and adjusted operating profit increased 36.8% due to higher revenue at Torii Pharmaceutical. - FY2022-Q1Higher revenue and profitsAnnual report
「Revenue increased 8.3% year on year due to higher revenue at Torii Pharmaceutical, a consolidated subsidiary. Adjusted operating profit increased 8.0% year on year due to higher revenue despite increased R&D expenses.」
Revenue in the pharmaceutical business increased due to higher revenue at Torii Pharmaceutical, and adjusted operating profit also increased 8.0% year on year despite increased R&D expenses. - FY2021Higher sales, lower operating incomeAnnual report
「Revenue increased 1.8% year on year as higher revenue at Torii Pharmaceutical, a consolidated subsidiary, more than offset lower overseas royalty income. Adjusted operating profit decreased 35.4% year on year due to increased R&D expenses and lower profit at Torii Pharmaceutical.」
Revenue in the pharmaceutical business increased, while adjusted operating profit declined due to increased R&D expenses and lower profit at Torii Pharmaceutical. - FY2021-Q3Lower revenue and profitAnnual report
「Revenue decreased 1.3% year on year despite higher revenue at Torii Pharmaceutical, a consolidated subsidiary, due to lower overseas royalty income and other factors. Adjusted operating profit decreased 47.6% year on year due to lower revenue, increased R&D expenses and lower profit at Torii Pharmaceutical.」
In the pharmaceutical business, revenue declined due to lower overseas royalty income and other factors, while adjusted operating profit decreased 47.6% due in part to increased R&D expenses and lower profit at Torii Pharmaceutical. - FY2021-Q2Lower revenue and profitAnnual report
「Revenue decreased 0.6% year on year despite higher revenue at Torii Pharmaceutical, a consolidated subsidiary, due to lower overseas royalty income and other factors. Adjusted operating profit decreased 55.2% year on year due to the recognition of a loss on disposal following the discontinuation of development of an in-licensed product and lower profit at Torii Pharmaceutical.」
In the pharmaceutical business, revenue decreased 0.6% due to lower overseas royalty income and other factors, while adjusted operating profit decreased 55.2% due to a loss on disposal following the discontinuation of development of an in-licensed product and lower profit at Torii Pharmaceutical. - FY2021-Q1Lower revenue and profitAnnual report
「Revenue decreased 5.2% year on year due to lower overseas royalty income and other factors. Adjusted operating profit decreased 35.7% year on year due to lower revenue and lower profit at Torii Pharmaceutical, a consolidated subsidiary of the company.」
In the pharmaceutical business, revenue declined due to lower overseas royalty income and other factors, and adjusted operating profit also declined due in part to lower profit at Torii Pharmaceutical. - FY2020Revenue Decline, Profit GrowthAnnual report
「Revenue decreased 10.8% year on year due to lower overseas royalty income and other factors. Adjusted operating profit increased 7.6% year on year despite lower revenue, due to lower R&D expenses following the completion of trials for products for which marketing approval applications had been filed, as well as higher profit at Torii Pharmaceutical.」
In the pharmaceutical business, revenue declined due to lower overseas royalty income and other factors, while adjusted operating profit increased 7.6% due to lower R&D expenses and higher profit at Torii Pharmaceutical. - FY2020-Q3Revenue Decline, Profit GrowthAnnual report
「Revenue decreased 9.1% year on year due to lower overseas royalty income and other factors. The impact of the spread of COVID-19 on revenue was considered minor. Adjusted operating profit increased 61.4% year on year despite lower revenue, due to lower R&D expenses following the completion of trials for products for which marketing approval applications had been filed, as well as higher profit at Torii Pharmaceutical Co., Ltd., a group company.」
In the pharmaceutical business, revenue declined due to lower overseas royalty income and other factors, while adjusted operating profit increased 61.4% due to lower R&D expenses following the completion of trials for development products and higher profit at Torii Pharmaceutical. - FY2020-Q2Revenue Decline, Profit GrowthAnnual report
「Revenue decreased 10.8% year on year due to lower overseas royalty income and other factors. The impact of the spread of COVID-19 on revenue was considered minor. Adjusted operating profit increased 38.8% year on year despite lower revenue, due to lower R&D expenses following the completion of trials for products for which marketing approval applications had been filed, as well as higher profit at Torii Pharmaceutical Co., Ltd., a group company.」
In the pharmaceutical business, revenue declined due to lower overseas royalty income and other factors, while adjusted operating profit increased 38.8% due to lower R&D expenses following the completion of trials and higher profit at Torii Pharmaceutical. - FY2020-Q1Revenue Decline, Profit GrowthAnnual report
「Revenue decreased 9.0% year on year despite strong sales at Torii Pharmaceutical Co., Ltd., a group company, due to lower overseas royalty income and other factors. Adjusted operating profit increased 47.1% year on year despite lower revenue, due to lower R&D expenses following the completion of trials and other factors, as well as higher profit at Torii Pharmaceutical Co., Ltd.」
In the pharmaceutical business, revenue declined due to lower overseas royalty income and other factors, while adjusted operating profit increased 47.1% due to lower R&D expenses following the completion of trials and higher profit at Torii Pharmaceutical. - FY2019ReframedAnnual report
「To make a stable contribution to earnings, we will work to further strengthen our earnings base, with the advancement of R&D for next-generation strategic products and out-licensing at the optimal timing, as well as maximizing the value of each product, as key priorities.」
Regarding the strengthening of the pharmaceutical business earnings base, the optimal timing for out-licensing was specified in addition to the existing focus on R&D and maximizing product value. - FY2019-Q3Lower revenue and profit due to the termination of license agreementsAnnual report
「Revenue decreased 22.6% year on year due to the impact of the termination of domestic license agreements for 6 anti-HIV drugs and lower overseas royalty income. Adjusted operating profit decreased 59.4% year on year due to lower revenue.」
In the pharmaceutical business, revenue decreased 22.6% and adjusted operating profit decreased 59.4% due, among other factors, to the termination of domestic license agreements for 6 anti-HIV drugs. - FY2019-Q2Lower revenue and profit due to the termination of license agreementsAnnual report
「Revenue decreased 21.4% year on year due to the impact, among other factors, of the termination of domestic license agreements for 6 anti-HIV drugs. Adjusted operating profit decreased 49.8% year on year due to lower revenue.」
In the pharmaceutical business, revenue decreased 21.4% and adjusted operating profit decreased 49.8% due to the impact of the termination of domestic license agreements for 6 anti-HIV drugs. - FY2019-Q1Lower revenue and profit due to the termination of license agreementsAnnual report
「Revenue decreased 14.6% year on year due to the termination, among other factors, of domestic license agreements with partner companies for 6 anti-HIV drugs. Adjusted operating profit decreased 41.9% year on year due to lower revenue and increased R&D expenses.」
In the pharmaceutical business, revenue and adjusted operating profit declined due to the termination of domestic license agreements for 6 anti-HIV drugs and increased R&D expenses. - FY2018AdvancedAnnual report
「Revenue increased 8.9% year on year due to increased royalty income accompanying higher sales of out-licensed products and milestone income related to out-licensed products. Adjusted operating profit increased 18.0% year on year due to higher revenue despite increased R&D expenses.」
In the pharmaceutical business, revenue increased 8.9% and adjusted operating profit increased 18.0% due to royalty income and milestone income from out-licensed products. - FY2018-Q3AdvancedAnnual report
「We aim to make a stable contribution to group earnings by advancing the R&D of next-generation strategic products and maximizing the value of each product. In terms of development progress, 7 products are currently in the clinical development stage. Revenue for the nine-month period ended under review increased by ¥7.5 billion year on year to ¥81.8 billion, up 10.1%, mainly due to increased royalty income accompanying higher sales of out-licensed products. Adjusted operating profit increased by ¥3.5 billion year on year to ¥19.3 billion, up 21.8%, due to higher revenue despite increased R&D expenses.」
The number of products in clinical development increased from 6 in the previous quarter to 7, while revenue in the pharmaceutical business increased 10.1% and adjusted operating profit increased 21.8%. - FY2018-Q2Fewer products in clinical development; higher revenue and profitAnnual report
「We aim to make a stable contribution to group earnings by advancing the R&D of next-generation strategic products and maximizing the value of each product. In terms of development progress, 6 products are currently in the clinical development stage. Revenue for the six-month period ended under review increased by ¥6.0 billion year on year to ¥53.2 billion, up 12.7%, due to increased royalty income accompanying higher sales of out-licensed products and strong sales at Torii Pharmaceutical Co., Ltd., a group company, despite the impact of a drug price revision. Adjusted operating profit increased by ¥2.4 billion year on year to ¥11.4 billion, up 26.7%, despite higher R&D expenses, due to higher revenue.」
In the pharmaceutical business, the number of products in clinical development decreased from 8 to 6, while revenue increased 12.7% and adjusted operating profit increased 26.7%, due to royalty income and other factors. - FY2018-Q1AdvancedAnnual report
「We aim to make a stable contribution to group earnings by advancing the R&D of next-generation strategic products and maximizing the value of each product. In terms of development progress, 8 products are currently in the clinical development stage. Revenue for the first quarter of the fiscal year under review increased by ¥3.5 billion year on year to ¥26.7 billion, up 14.9%, due to increased royalty income accompanying higher sales of out-licensed products and strong sales at Torii Pharmaceutical Co., Ltd., a group company. Adjusted operating profit increased by ¥2.6 billion year on year to ¥7.7 billion, up 52.1%, due to higher revenue.」
The number of products in clinical development remained at 8, while revenue in the pharmaceutical business increased 14.9% and adjusted operating profit increased 52.1%, due to royalty income from out-licensed products and other factors. - FY2017AdvancedAnnual report
「We aim to make a stable contribution to group earnings by advancing the R&D of next-generation strategic products and maximizing the value of each product. In terms of development progress, 8 products are currently in the clinical development stage. Revenue for the fiscal year under review increased by ¥17.5 billion year on year to ¥104.7 billion, up 20.1%, due to increased royalty income accompanying higher sales of out-licensed products and strong sales at Torii Pharmaceutical, a group company. Adjusted operating profit increased by ¥14.4 billion year on year to ¥24.1 billion, up 148.0%, due to higher revenue.」
The number of products in clinical development increased from 7 to 8, and revenue and adjusted operating profit in the pharmaceutical business also increased. - FY2017-Q3AdvancedAnnual report
「We aim to make a stable contribution to group earnings by advancing the R&D of next-generation strategic products and maximizing the value of each product. In terms of development progress, 7 products are currently in the clinical development stage. Revenue for the nine-month period ended under review increased by ¥13.5 billion year on year to ¥74.2 billion, up 22.2%, due to increased royalty income accompanying higher sales of out-licensed products and strong sales at Torii Pharmaceutical Co., Ltd., a group company. Adjusted operating profit increased by ¥11.6 billion year on year to ¥15.8 billion, up 274.4%, due to higher revenue.」
The number of products in clinical development remained at 7, while revenue in the pharmaceutical business increased 22.2% and adjusted operating profit increased 274.4%, mainly due to higher royalty income from out-licensed products. - FY2017-Q2AdvancedAnnual report
「Revenue for the six-month period ended under review increased by ¥6.9 billion year on year to ¥47.2 billion, up 17.1%, mainly due to increased royalty income accompanying higher sales of out-licensed products. Adjusted operating profit increased by ¥6.2 billion year on year to ¥9.0 billion, up 224.5%, due to higher revenue.」
The number of products in clinical development remained at 7, while adjusted operating profit in the pharmaceutical business increased 224.5% year on year due to royalty income accompanying higher sales of out-licensed products. - FY2017-Q1AdvancedAnnual report
「Revenue for the first quarter of the fiscal year under review increased by ¥1.7 billion year on year to ¥23.2 billion, up 7.7%, mainly due to increased royalty income accompanying higher sales of out-licensed products. Adjusted operating profit increased by ¥1.9 billion year on year to ¥5.1 billion, up 58.9%, due to higher revenue.」
Adjusted operating profit in the pharmaceutical business increased 58.9% year on year due to higher royalty income accompanying increased sales of out-licensed products. The number of products in clinical development was 7. - FY2016AdvancedAnnual report
「During the fiscal year under review, we obtained marketing approval in Japan for the anti-HIV drugs Genvoya tablets and Descovy tablets LT and HT, and Torii Pharmaceutical, a group company, began sales in July 2016 and January 2017, respectively.」
Marketing approval in Japan was obtained for 2 anti-HIV drugs, and sales began in July 2016 and January 2017. Meanwhile, the number of products in clinical development was stated to be 7. - FY2016-Q3AdvancedAnnual report
「In terms of development progress, 9 products are currently in the clinical development stage. Of these, we filed an application in Japan in August 2016 for marketing approval of the anti-HIV drug emtricitabine/tenofovir alafenamide fumarate combination tablets.」
The number of products in clinical development remained at 9, and the planned Japanese marketing approval application for the anti-HIV drug was filed in August 2016. The pharmaceutical business generated revenue of ¥60.7 billion and adjusted operating profit of ¥4.2 billion. - FY2016-Q2First statedAnnual report
「We aim to make a stable contribution to group earnings by advancing the R&D of next-generation strategic products and maximizing the value of each product. In terms of development progress, 9 products are currently in the clinical development stage, following the addition of 2 products. Of the products in clinical development, we plan to file an application in Japan in the third quarter of the fiscal year ending December 2016 for marketing approval of the anti-HIV drug emtricitabine/tenofovir alafenamide fumarate combination tablets. During the second quarter under review, we obtained marketing approval in Japan in June 2016 for the anti-HIV drug Genvoya tablets, and Torii Pharmaceutical Co., Ltd., a group company, began sales in July.」
The number of products in clinical development increased to 9, with 2 new products entering the clinical stage. For the anti-HIV drugs, the disclosure states that marketing approval was obtained, sales began, and a marketing approval application is scheduled.